What is Roivant?
Founded in 2014 and headquartered in London, Roivant Sciences operates as a tech-enabled healthcare company. Its core mission is to accelerate the development of promising late-stage drug candidates and to bring innovative healthcare technologies to patients. By leveraging a robust technological infrastructure, Roivant aims to streamline the drug development process and enhance patient access to novel treatments, positioning itself as a key player in the evolving healthcare landscape.
How much funding has Roivant raised?
Roivant has raised a total of $1.4B across 3 funding rounds:
Private Equity
$100M
Private Equity
$1.1B
Private Equity
$200M
Private Equity (2014): $100M with participation from QVT Financial and Dexcel Pharma
Private Equity (2017): $1.1B led by Dexcel Pharma and Softbank
Private Equity (2018): $200M supported by NovaQuest Capital Management and RTW Investments
Key Investors in Roivant
Dexcel Pharma
Dexcel Pharma, Israel's largest privately owned pharmaceutical company, contributes its extensive experience in developing and commercializing a wide range of pharmaceutical products, including branded prescription drugs and generics, to Roivant's strategic growth.
Softbank
SoftBank Group Corp., a global technology holding company, provides strategic capital and expertise in telecommunications, internet services, and artificial intelligence, supporting Roivant's innovation in healthcare technology.
RTW Investments
RTW Investments, a life sciences investment firm, offers deep scientific knowledge and capital to support Roivant's development of transformative biotech and medtech innovations aimed at improving patient lives.
What's next for Roivant?
The recent major strategic investment signals Roivant's readiness for its next phase of expansion and innovation. This capital infusion is expected to fuel further research and development, potentially leading to the advancement of its drug pipeline and the scaling of its healthcare technology solutions. Roivant's strategic approach to drug development, combined with significant financial backing, positions it to address unmet medical needs and drive meaningful advancements in patient care.
See full Roivant company page
